Advertisement
Home Tags Drug Approvals

Tag: Drug Approvals

Vistogard (uridine triacetate) has been approved by the U.S. Food and Drug Administration to treat an overdose of the chemotherapy drugs fluorouracil and capecitabine

FDA Approves Vistogard to Treat Chemotherapy Overdose

0
For overdose of the chemo drugs fluorouracil and capecitabine
Alecensa (alectinib) has been approved by the U.S. Food and Drug administration to treat anaplastic lymphoma kinase-positive non-small-cell lung cancer

FDA Approves Alecensa for ALK-Positive NSCLC

0
Drug is designed to block the effects of the ALK protein
The Dignitana DigniCap Cooling System cap has been approved by the U.S. Food and Drug Administration to help prevent hair loss in women undergoing chemotherapy for breast cancer.

FDA Approves Cooling Cap to Reduce Chemo-Linked Hair Loss

0
Designed for women diagnosed with breast cancer
Kanuma (sebelipase alfa) has been approved by the U.S. Food and Drug Administration as the first treatment for LAL deficiency (Wolman disease or cholesteryl ester storage disease).

FDA Approves Kanuma for Lysosomal Acid Lipase Deficiency

0
For treatment of LAL deficiency, also known as Wolman disease or cholesteryl ester storage disease
Vonvendi has been approved by the U.S. Food and Drug Administration to treat adults with von Willebrand disease.

FDA Approves Vonvendi to Treat von Willebrand Disease

0
Approved for the as-needed treatment and control of bleeding episodes in adults
The first seasonal influenza vaccine with an adjuvant has been approved for use in seniors

FDA Approves First Flu Vaccine Containing an Adjuvant

0
Adjuvant can enhance or direct the immune response of the vaccinated individual
Empliciti (elotuzumab)

FDA Approves Empliciti for Multiple Myeloma

0
Monoclonal antibody works with another approved therapy to provide additional benefit
Portrazza (necitumumab)

FDA Approves Portrazza for Advanced Squamous NSCLC

0
Drug is designed to block activity of epidermal growth factor receptor protein
U.S. Food and Drug Administration approval for the BioThrax anthrax vaccine has been expanded to include adults aged 18 to 65 with known or suspected exposure

FDA Expands Anthrax Vaccine Approval

0
Now sanctioned for adults 18 to 65 with known or suspected exposure
Opdivo (nivolumab) has been approved by the U.S. Food and Drug Administration to treat advanced renal cell carcinoma.

FDA Approves Opdivo for Advanced Renal Cell Carcinoma

0
Drug works by targeting the PD-1/PD-L1 cellular pathway